Asset Details
Do you wish to reserve the book?
Demographic and clinical characteristics of patients with metastatic breast cancer and leptomeningeal disease: a single center retrospective cohort study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Demographic and clinical characteristics of patients with metastatic breast cancer and leptomeningeal disease: a single center retrospective cohort study
Do you wish to request the book?
Demographic and clinical characteristics of patients with metastatic breast cancer and leptomeningeal disease: a single center retrospective cohort study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Demographic and clinical characteristics of patients with metastatic breast cancer and leptomeningeal disease: a single center retrospective cohort study
2024
Overview
Purpose
Leptomeningeal disease (LMD) is a devastating complication of metastatic breast cancer (MBC). It is critical to better understand the risk factors, natural history, and treatment outcomes, including patients in a modern cohort.
Methods
In this single center retrospective cohort study, we identified patients with MBC and LMD who received care from 2000 to 2024 and abstracted key clinical, treatment, and survival data.
Results
We identified 111 patients with MBC and LMD, including patients with the following subtypes: HR+/HER2− (
n
= 53, 47.7%), HER2+ (
n
= 30, 27.0%), and triple negative breast cancer (TNBC;
n
= 28, 25.2%). Median time from the diagnosis of MBC to LMD was 16.4 months (range 0–101.3 months). After the diagnosis of LMD, most patients received systemic therapy (
n
= 66, 59.5%) and/or central nervous system (CNS)-directed therapy (
n
= 94, 84.7%) including intrathecal therapy (
n
= 42, 37.8%) and/or CNS-directed radiation therapy (
n
= 70, 63.1%). In all patients, median overall survival (OS) from the diagnosis of LMD to death was 4.1 months (range 0.1–78.1 months) and varied by subtype, with HR+/HER2− or HER2+ MBC patients living longer than those with TNBC (4.2 and 6.8 months respectively vs. 2.0 months,
p
< 0.01, HR 2.15, 95% CI 1.36–3.39). Patients who received CNS-directed therapy lived longer than those who did not (4.2 vs. 1.3,
p
= 0.02 HR 0.54, 0.32–0.91). Patients diagnosed with LMD from 2015 to 2024 lived longer than those diagnosed from 2000 to 2014 (6.4 vs. 2.9 months,
p
= 0.04, HR 0.67, 95% CI 0.46–0.99). On multivariable analysis, having TNBC was associated with shorter OS from time of LMD to death (
p
= 0.004, HR 2.03, 95% CI 1.25–3.30).
Conclusion
This is one of the largest case series of patients with MBC and LMD. Patients diagnosed with LMD from 2015 to 2024 lived longer than those diagnosed from 2000 to 2014, although median OS was short overall. Patients with TNBC and LMD had particularly short OS. Novel therapeutic strategies for LMD remain an area of unmet clinical need.
Publisher
Springer US,Springer,Springer Nature B.V
Subject
/ Aged
/ Breast Neoplasms - mortality
/ Breast Neoplasms - pathology
/ Cancer
/ Diseases
/ Female
/ Humans
/ Medicine
/ Meningeal Carcinomatosis - mortality
/ Meningeal Carcinomatosis - secondary
/ Meningeal Carcinomatosis - therapy
/ Meningeal Neoplasms - mortality
/ Meningeal Neoplasms - secondary
/ Meningeal Neoplasms - therapy
/ Meninges
/ Oncology
/ Patients
/ Receptor, ErbB-2 - metabolism
/ Survival
